{"id":"hcp1102","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HCP1102 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms seen with conventional anti-androgens.","oneSentence":"HCP1102 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:39.519Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer (CRPC)"}]},"trialDetails":[{"nctId":"NCT04324918","phase":"PHASE3","title":"Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-23","conditions":"Perennial Allergic Rhinitis","enrollment":174},{"nctId":"NCT03371849","phase":"PHASE1","title":"PK and Safety Study of HCP1102, HGP0813 and HGP1408","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2017-07-19","conditions":"Healthy","enrollment":24},{"nctId":"NCT02552667","phase":"PHASE3","title":"Efficacy and Safety of HCP1102 Capsule","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-09","conditions":"Asthma With Allergic Rhinitis","enrollment":228},{"nctId":"NCT01651481","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2012-07","conditions":"Rhinitis","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Singulair and Xyzal combination tablet"],"phase":"phase_3","status":"active","brandName":"HCP1102","genericName":"HCP1102","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1102 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}